Partners at CCMI, NUI Galway offer training workshops

Our partners at the Centre for Cell Manufacturing Ireland (CCMI) based at the National University of Ireland Galway have organized a workshop series:  “Selection, Validation and Implementation of Rapid Microbiological Methods for ATMPs“. This event will take place in Galway, Ireland on the 12th and 13th of June 2019.

For more information, download the flyer here.

ADIPOA-2 work featured in Italian health magazine “Viversani”

The work of the ADIPOA-2 teams at the Universita Degli Studi di Padova and the Rizzoli Orthopaedic Institute has recently been featured in the popular press health magazine “Viversani” or “To Life with Health”. On pages 46-47, find the article Dal “grasso” un aiuto contro l’osteoartrosi  where Prof Riccardo Meliconi of the Reumatologia all’Instituto Ortopedico Rizzoli di Bologna and Prof Roberta Ramonda of the Rheumatology Unit University of Padova-Italy have consulted with the reporter Chiara Di Paola to feature the research.

Rizzoli Orthopaedic Institute researchers present ADIPOA-2 widely

Researchers at the Rizzoli Orthopaedic Institute in Bologna have been busy presenting ADIPOA-2 findings at a variety of national and international conferences. Below please find a list of their dissemination activities to inform and educate others in the research community of our scientific plan and findings.

  1. Oral presentation at “Le Cellule Staminali nella Medicina”. Round table forum: LE CELLULE STAMINALI NELLA MEDICINA TRASLAZIONALE “: Cellule Staminali e Osteoartrite: Il Progetto ADIPOA-2; Gina Lisignoli and Riccardo Meliconi
  2. Oral presentation at the ICRS 2018, 13-14 December 2018 Milan, Italy. Title: ADIPOA Project: Adipose-Derived Stem Cells Biological Effects; Gina Lisignoli.
  3. Oral presentation at the AICC (31st annual conference of Italian Association of Cell Culture), 27-28 November 2018 Bologna, Italy. Title: Mesenchymal stem cells and synoviocytes:development of an in vitro co-culture model; Gina Lisignoli.
  4. Oral presentation at the EORS 2018, 25- 28 September 2018, Galway, Ireland. Title: Adipose mesenchymal stromal cells characteristics are differently modulated by osteoarthritic milieu. Cristina Manferdini, Francesca Paolella, Elena Gabusi, Luca Cattini, Hubert Schrezenmeier, Gina Lisignoli.
  5. Oral presentation at the EORS 2018, 25- 28 September 2018, Galway, Ireland. Title: Switching of the pro-inflammatory profile of synovial osteoarthritic macrophages by adipose mesenchymal stromal cells; Cristina Manferdini, Francesca Paolella, Elena Gabusi, Laura Gambari,  Sandrine Fleury-Cappellesso, Andrea Barbero,  Mary Murphy, Gina Lisignoli.
  6. Oral presentation at OARSI 2018,  26 -29 April 2018, Liverpool, UK. Title: Adipose mesenchymal stromal cells determine the switching of the pro-inflammatory profile of synovial osteoarthritic macrophages; Cristina Manferdini, Francesca Paolella, Elena Gabusi, Laura Gambari,  Giuseppe Filardo, Sandrine Fleury-Cappellesso, Andrea Barbero,  Mary Murphy, Gina Lisignoli.
  7. Poster presentation at the SCR meeting 25-27 May 2017, Chieti, Italy. Title: Switching of a M1 inflammatory macrophages subset by adipose stromal cells contributes to resolution of osteoarthritic synovial tissue inflammation; C Manferdini, F Paolella, E Gabusi, L Gambari, L Cattini, A Piacentini, S Fleury-Cappellesso, A Barbero, M Murphy, G Lisignoli.
  8. Poster presentation at the EULAR 2017 14-17 June 2017 Madrid, Spain. Title: Adipose stromal cells exert specific effects on osteoarthritic synovial macrophages; Manferdini C, Paolella F., Gabusi E., Piacentini A., Gambari L., Cattini L., Fleury-Cappellesso S., Lisignoli G
  9. Oral presentation at the ICRS held 24-27 September 2016, Sorrento, IT. Title: Adipose stromal cells exert specific effects on osteoarthritic synovial macrophages; Manferdini C, Paolella F., Gabusi E., Piacentini A., Gambari L., Cattini L., Fleury-Cappellesso S.,  Lisignoli G.
  10. Poster presentation at TERMIS 27 June-04 July 2016, Uppsala, Sweden Title: Adipose stromal cells effects on osteoarthritic synovial cells are dependent by macrophages; C Manferdini, F Paolella, E Gabusi, L Gambari, L Cattini, S Fleury-Cappellesso, A Barbero, G Lisignoli.
  11. Poster presentation at the OARSI 2016 World Congress, March 31-April 3 Amsterdam, Netherlands. Title: Adipose stromal cells effects on osteoarthritic synoviocytes are dependent by macrophages; Manferdini C,  Gabusi E., Piacentini A.,  Paolella F., Fleury-Cappellesso S., Jorgensen C., Noël D., Barbero A., Lisignoli G.
  12. Poster presentation at the SCR meeting 21– 23 June 2016 Bologna, Italy. Title: Adipose stromal cells effects on osteoarthritic synovial cells are dependent by macrophages; C Manferdini1, F Paolella1, E Gabusi1, L Gambari, L Cattini, S Fleury-Cappellesso, A Barbero4, G Lisignoli

Frank Barry gives keynote presentation at Zoobiquity Colorado meeting

On October 5 and 6, 2018, Zoobiquity Colorado: Connecting Human and Animal Health through Regenerative Medicine will take place. Here, ADIPOA-2 Coordinator Prof Frank Barry of the Regenerative Medicine Institute at the National University of Ireland Galway will deliver a keynote presentation, ‘Cell Strategies for Arthritic Disease’.

Zoobiquity Colorado aims to uncover the astonishing connection between human and animal health by highlighting laboratory and clinical research of human and veterinary investigators and fostering future collaboration across disciplines.

Prof Frank Barry takes ADIPOA-2 on the road

ADIPOA-2 Coordinator Professor Frank Barry of NUI Galway has had a busy 2018 thus far. He has organised and been invited to present at several conferences, provide keynote talks and lead seminars around the world raising the profile of ADIPOA-2 internationally within academic and industrial circles.

Here is a list of events:

  1. Speaker on August 17 2018: Georgia Tech CMaT Annual Retreat, Madison WI, USA
  2. Invited Seminar on July 23 2018: Colorado State University Veterinary Orthopaedic Centre Fort Collins, CO, USA
  3. Keynote Speaker on July 6 2018: Whitaker Bioengineering Symposium, Galway, Ireland
  4.  Keynote Speaker; Conference and workshop organiser on June 28 2018: CALIN Cell and Gene Therapy Industry Symposium, Galway, Ireland
  5.  Invited Seminar on June 7 2018: University of Guelph School of Veterinary Medicine, Guelph, ON, Canada
  6.  Keynote Speaker on May 24 2018: Canadian Connective Tissue Conference, Toronto, ON, Canada
  7. Plenary Speaker on May 18 2018: American Society for Gene and Cell Therapy Annual Conference, Chicago, IL, USA
  8.  Keynote Speaker on May 12 2018: Canadian Bone and Joint Conference, London ON, Canada
  9. Plenary Speaker on May 2 2018: International Society for Cellular Therapy Annual Conference, Montreal, QC, Canada
  10.  Seminar Speaker in January 2018: Division of Orthopaedics, University of Toronto, ON, Canada

Here is some digital press coverage from the roadshow:


ADIPOA-2 features in Azienza Opedaliera di Padova June newsletter 2018

On pages 8-12 of the June 2018 Informasanità, the Azienda Ospedaliera di Padova newsletter, ADIPOA-2 is featured. The role within the project and the team at the Rheumatology Unit, Department of Medicine – DIMED, University of Padova (UNIPD) are highlighted.

Read the entire publication here:  INFORMASANITA-GIUGNO-2018

Read more about the Rheumatology Unit of the Department of Medicine (DIMED) of University of Padova here.

Cell and Gene Therapy Industry Forum in Galway addresses opportunities for innovation

Leaders in industry and science met and discussed recent advances in cell and gene therapy research and development at an industry-focused event held on Thursday, June 28, 2018, at the Meyrick Hotel in Galway, Ireland.  Industry representation included presentations from Takeda, ReNeuron, Avectas and Valitacell. ADIPOA-2 Coordinator Prof Frank Barry presented the project’s mission, progress and innovative aspects.

The emerging fields of cell and gene therapy are considered by many to be the next revolution in medicine, promising unprecedented and previously unimaginable treatments for major life-altering conditions and degenerative diseases. There are few areas of biomedical research which have attracted so much attention in recent years and been surrounded by so much expectation and promise. However, serious challenges remain in addressing manufacturing efficiency, cost reduction, clinical trials and delivery to patients.

The event sponsors were The Celtic Advanced Life Science Innovation Network, an Ireland Wales 2014-2020 programme partially funded by the European Regional Development Fund through the Welsh Government.

Speakers included: Robin Ali, University College London, Frank Barry REMEDI at NUI Galway, John Sinden, ReNeuron, Michael McGuire Avectas, Andrew Finnerty CCMI, Maria del Pilar Redondo, Takeda Europe, Mary Murphy REMEDI at NUI Galway, Stephanie Davis Valitacell and Gerry McCauliffe of Omnispirant.

Read the entire event programme: CALIN Galway Programme. 

ADIPOA-2 clinical study highlighted in University of Padua publication

On March 29, 2018, the online magazine Il Bo published an update on the ADIPOA-2 clinical trial ongoing at the University of Padua and other sites. Read the story here.


New ADIPOA2 research published from Centre Hospitalier Universitaire Montpellier

‘Mesenchymal stem cells derived exosomes and microparticles protect cartilage and bone from degradation in osteoarthritis’ by authors: Stella CosenzaMaxime RuizKarine ToupetChristian Jorgensen & Danièle Noël was published online on 24 November 2017 in the open access Nature publication Scientific Reports.

Abstract: Mesenchymal stem or stromal cells (MSCs) exert chondroprotective effects in preclinical models of osteoarthritis (OA). Most of their therapeutic effects are mediated via soluble mediators, which can be conveyed within extracellular vesicles (EVs). The objective of the study was to compare the respective role of exosomes (Exos) or microvesicles/microparticles (MPs) in OA. MPs and Exos were isolated from bone marrow murine BM-MSCs through differential centrifugation. Effect of MPs or Exos was evaluated on OA-like murine chondrocytes and chondroprotection was quantified by RT-qPCR. In OA-like chondrocytes, BM-MSC-derived MPs and Exos could reinduce the expression of chondrocyte markers (type II collagen, aggrecan) while inhibiting catabolic (MMP-13, ADAMTS5) and inflammatory (iNOS) markers. Exos and MPs were also shown to protect chondrocytes from apoptosis and to inhibit macrophage activation. In vivo, Exos or MPs were injected in the collagenase-induced OA (CIOA) model and histomorphometric analyses of joints were performed by µCT and confocal laser microscopy. BM-MSCs, MPs and Exos equally protected mice from joint damage. In conclusion, MPs and Exos exerted similar chondroprotective and anti-inflammatory function in vitro and protected mice from developing OA in vivo, suggesting that either Exos or MPs reproduced the main therapeutic effect of BM-MSCs.

Read more about the role of Centre Hospitalier Universitaire Montpellier in ADIPOA2 here.

Scientific Reports 7, Article number 16214 (2017)

Doi: 10.1038/s4 1598-017-15376-8

Published online 24 November 2017-11-29

Read the entire paper here.



Sports Surgery Clinic Plays Leading Role in European Clinical Trial on Stem Cell Therapy for Osteoarthritis of the Knee

Prevention of progression of Osteoarthritis will improve the lives of millions of sufferers

Tuesday, 12th May 2015: The Sports Surgery Clinic in Santry has today announced it’s participation in the ADIPOA-2 stem cell trial for Osteoarthritis (OA), the aim of which is to find treatment(s) for the disease and prevent it’s progression.

This large-scale clinical trial using adult stem cells to treat knee osteoarthritis is expected to be underway across Europe by the end of 2015. Almost €6 million has been granted to the project ‘ADIPOA-2’ by the EU’s Horizon 2020 research funding programme.

Osteoarthritis (OA) is an incurable and degenerative disease of the joints. Osteoarthritis has been identified as the eleventh highest contributor to disability and affects over 70 million people throughout Europe. There is currently no treatment to prevent progression of the disease.

ADIPOA-2 is contributing to the development of a novel cellular therapy for the treatment of osteoarthritis. The Sports Surgery Clinic’s participation in the programme is being led by Professor Cathal Moran, Consultant Orthopaedic Surgeon and Professor and Chair of Orthopaedics and Sports Medicine at Sports Surgery Clinic and Trinity College Dublin.

Sports Surgery Clinic is one of Ireland’s leading providers of clinical care in orthopaedics and sports medicine. Professor Cathal Moran has extensive international clinical and academic experience in orthobiological therapies as an orthopaedic surgeon specialising in Knee and Shoulder surgery and shall act as the Lead Knee Surgeon at SSC for ADIPOA-2. Under Professor Cathal Moran’s direction, Sports Surgery Clinic will facilitate the recruitment and treatment or trial participants as part of the multicentre international trial.

The overall scientific programme is being led by Professor Frank Barry, Scientific Director of the Regenerative Medicine Institute (REMEDI) at the National University of Ireland Galway. ADIPOA is a multi-phase programme of research in exploring new treatments for Osteoarthritis. In its first phase, the EU consortium ADIPOA1 carried out a first-in-man Phase I safety study in 18 patients. This study demonstrated that a single dose of stem cells cultured from the patients’ own fatty tissue (autologous adipose-derived mesenchymal stromal cells (ASCs)) injected into the knee was well tolerated, had no adverse effects, and resulted in an improvement in pain score and functional outcome. The results of this were sufficiently encouraging to warrant a larger, multi-centre Phase 2b trial to further test the safety and efficacy of autologous (patient derived) ACSs in the treatment of advanced OA of the knee. ADIPOA-2 will now build on the work of ADIPOA1 to deliver a randomised clinical trial across 10 hospitals in Europe involving 150 patients.

Speaking about the research Professor Cathal Moran said, “We are delighted at Sports Surgery Clinic to be participating in this landmark international clinical trial. Finding new ways to help delay the deterioration of joints caused by Osteoarthritis will improve the lives of millions of people worldwide, relieving them from debilitating pain, and helping them to continue an active life. Large scale stem cell research is in itself incredibly exciting and we look forward to contributing in the next phase of the programme. The specialised environment of Sports Surgery Clinic is an ideal environment in which to deliver highly regulated and controlled clinical trials”.

The international ADIPOA-2 clinical team includes clinicians from ten centres across Europe, including France, Germany, Italy, The Netherlands and two in Ireland – Sports Surgery Clinic in Dublin, and REMEDI in Galway. The first meetings of the ADIPOA-2 team took place in December last year in Paris, followed up by plenary planning meetings in Dublin in January 2015. The clinical trial will be delivered in conjunction with the National Clinical Research Facilities in Galway and Dublin. Clinical trial arrangements are being put in place at the partner institutes across Europe and Ireland and patient recruitment is anticipated in the first quarter of 2016.

Anyone interested in the programme; patients, doctors and other healthcare providers, are welcome to contact Professor Cathal Moran or Sports Surgery Clinic for more information. See and

For more information please contact:

Mary Gleeson | 086 2213077 |

About Professor Cathal Moran:

Professor Cathal Moran is the Professor and Chair of Orthopaedics and Sports Medicine at Trinity College Dublin and Consultant Orthopaedic Surgeon at Sports Surgery Clinic, Santry. He has also recently been appointed Honorary Professor at Royal College of Surgeons in Ireland and a Professorial Fellow of Trinity.

The new Academic Orthopaedic Unit at Trinity is only the second such academic unit in Ireland. In addition to it’s base in Orthopaedic Surgery, this is also the first ever Chair of Sports Medicine at an Irish University. The venture between Sports Surgery Clinic and Trinity College Dublin also represents the first time the clinical component of a Chair in a surgical discipline is hosted by a private hospital.

The Academic Unit of Orthopaedics and Sports Medicine in Trinity College Dublin’s School of Medicine will be be officially opened with the Inaugural Lecture of Cathal Moran, Professor of Orthopaedics and Sports Medicine in Trinity on May 13th at 18.00pm in the Trinity Biomedical Sciences Institute.

Professor Moran’s sub-specialty clinical interest is in the management of soft tissue and sports injuries, including ACL and ligament reconstruction, cartilage injury, meniscus repair and replacement, limb alignment surgery, rotator cuff and shoulder stabilisation surgery. He also performs shoulder and knee replacement surgery.

The new Academic Unit of Orthopaedics and Sports Medicine led by Professor Moran is based in the School of Medicine at Trinity College Dublin. The clinical host for the Chair is Sports Surgery Clinic and the unit functions in collaboration with Trinity Biomedical Sciences Institute, Trinity Centre for Bioengineering, and affiliated clinical sites.

In terms of research activity Professor Moran is a Principal Investigator at Trinity Centre for Bioengineering, RCSI Bioengineering and AMBER research centres. He links research at these centres to the development new options for treatment in Orthopaedics and Sports Medicine at Sports Surgery Clinic. His specific interest is in cartilage and soft tissue repair and regeneration, including the delivery of clinical trials in stem cell and biological treatment options for musculoskeletal injury and disease. Sports Surgery Clinic is host to many of these new trials.

Professor Moran completed his early training in Ireland, followed by sub-specialty training at the Orthopaedic Sports Medicine and Shoulder Fellowship at Hospital for Special Surgery and Cornell Medical College in New York, the Cartilage Repair Centre at Harvard Medical School and Brigham and Women’s Hospital in Boston, and Antwerp Orthopaedic Centre in Belgium.  He has also completed research periods at the Regenerative Medicine Institute (REMEDI) in Ireland; University of California, San Francisco; UC Irvine, California and Mayo Clinic in Rochester, Minnesota. He has worked extensively with professional athletes and teams across Ireland, the US and Europe, and has published over 50 papers and given over 200 presentations internationally.